추천 제품
제품명
Puromycin ready made solution, 10 mg/mL in H2O, ≥98% (HPLC), Cell culture tested
Quality Level
분석
≥98% (HPLC)
양식
liquid
농도
10 mg/mL in H2O
저장 온도
2-8°C
일반 설명
Puromycin is an aminonucleoside antibiotic naturally produced by Streptomyces alboniger as a tyrosyl tRNA analog. It inhibits ribosomal protein synthesis process by causing premature chain termination acting as an analog of the 3′-terminal end of the aminoacyl-tRNA. Puromycin also acts as a reversible inhibitor of dipeptidyl-peptidase II (serine peptidase) and cytosol alanyl aminopeptidase (100μM, IC50=0.6μM). Puromycin is used as a selection marker gene (puromycin-N-acetyltransferase gene, pac) in eukaryotic/mammalian cells.
Puromycin has a wide variety of biological activities with inhibitory effect against bacteria, protozoa, parasitic worms, algae, plants, and mammalian cells.
Puromycin shows broad spectrum activity, particularly strong activity against gram positive microorganisms but weak activity against acid-fast bacilli and even weaker activity against gram negative microorganisms.
Puromycin has anti-cancer properties, inducing apoptosis in breast cancer cells. It has been shown that Puromycin induces apoptosis in MCF-7 breast cancer cells using an immunological assay to study apoptosis (the modulating effect of insulin-like growth factor-1 (IGF-1)). Puromycin at 0.5 microg/ml induced a high level of apoptosis in MCF-7 breast cancer cells, although there was still a non-negligible amount of synthesized protein. The activity of Puromycin was compared to 2 other protein synthesis inhibitors (cycloheximide and emetine), in which apoptosis occurred when protein synthesis was almost completely blocked.
Puromycin also showed antitumor activity in MDA-MB-231 breast cancer cells, causing suppression of 45S pre-ribosomal RNA and upstream binding factor (UBF).
Furthermore, Puromycin was used to study the vascular smooth muscle cell viability after treatment in rabbit model.
Technical information
The suggested concentration of Puromycin in cell culture assays is 0.2-10-μg/mL. Therefore, it is recommended to dilute the ready made solution 1:1000-50,000.
Puromycin has a wide variety of biological activities with inhibitory effect against bacteria, protozoa, parasitic worms, algae, plants, and mammalian cells.
Puromycin shows broad spectrum activity, particularly strong activity against gram positive microorganisms but weak activity against acid-fast bacilli and even weaker activity against gram negative microorganisms.
Puromycin has anti-cancer properties, inducing apoptosis in breast cancer cells. It has been shown that Puromycin induces apoptosis in MCF-7 breast cancer cells using an immunological assay to study apoptosis (the modulating effect of insulin-like growth factor-1 (IGF-1)). Puromycin at 0.5 microg/ml induced a high level of apoptosis in MCF-7 breast cancer cells, although there was still a non-negligible amount of synthesized protein. The activity of Puromycin was compared to 2 other protein synthesis inhibitors (cycloheximide and emetine), in which apoptosis occurred when protein synthesis was almost completely blocked.
Puromycin also showed antitumor activity in MDA-MB-231 breast cancer cells, causing suppression of 45S pre-ribosomal RNA and upstream binding factor (UBF).
Furthermore, Puromycin was used to study the vascular smooth muscle cell viability after treatment in rabbit model.
Technical information
The suggested concentration of Puromycin in cell culture assays is 0.2-10-μg/mL. Therefore, it is recommended to dilute the ready made solution 1:1000-50,000.
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 2
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
시험 성적서(COA)
Evidence-based complementary and alternative medicine : eCAM, 2013, 879746-879746 (2013-05-22)
Since the dysregulation of ribosome biogenesis is closely associated with tumor progression, in the current study, the critical role of ribosome biogenesis related signaling was investigated in melatonin and/or puromycin induced apoptosis in MDA-MB-231 breast cancer cells. Despite its weak
Gene, 62(1), 121-126 (1988-01-01)
Recombinant plasmids have been obtained that lead to the accumulation of five- to ten-fold more puromycin-N-acetyl-transferase (PAC) mRNA and two- to three-fold more PAC activity than the already described plasmid pSV2pac [Vara et al., Nucl. Acids Res. 14 (1986) 4117-4124].
Gene, 534(2), 249-255 (2013-11-05)
A puromycin-N-acetyltransferase gene (pac) is widely used as a selection marker for eukaryotic gene manipulation. However, it has never been utilized for molecular studies in the ciliate Tetrahymena thermophila, in spite of the limited number of selection markers available for
Current opinion in structural biology, 8(3), 286-293 (1998-07-17)
Mimics recapitulating the structural features of tRNAs are involved in biological processes other than ribosome-dependent protein synthesis. A knowledge of the rules underlying the architecture and function of tRNAs allows the design of non-natural mimics. The study of these mimics
PUROMYCIN INHIBITION OF PROTEIN SYNTHESIS.
Pharmacological reviews, 16, 223-243 (1964-09-01)
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.